FDA Eases Path for Wearable Health Tech

The FDA's "General Wellness: Policy for Low Risk Devices" guidance clarifies its enforcement discretion for products promoting a healthy lifestyle. To qualify, devices must be non-invasive, not implanted, and present a low risk to user safety, focusing on claims related to improving or maintaining general health rather than diagnosing or treating specific diseases. This policy stems from the 21st Century Cures Act, which removed certain low-risk software functions from the formal definition of a medical device. This approach builds on learnings from the FDA's Software Precertification (Pre-Cert) Pilot Program, which ran from 2017 to 2022 and included participants like Apple, Fitbit, and Johnson & Johnson. The program explored certifying a developer's process rather than each individual product, a significant departure from traditional device regulation. Ultimately, the FDA concluded that a new legislative framework would be required to fully implement such a trust-based model. The global mHealth app market was estimated at $37.5 billion in 2024 and is projected to grow to over $86 billion by 2030. This growth is attracting significant venture capital, with U.S. digital health startups raising $14.2 billion in 2025, a 35% increase from the previous year. Investment is increasingly concentrated, with AI-enabled companies capturing 54% of total funding and commanding higher average deal sizes. AI and machine learning are central to the strategy of new consumer health apps, enabling a shift from basic tracking to predictive analytics for disease risk. Machine learning models are used to create personalized health recommendations and tailored messages, which can improve user engagement and adherence to wellness programs. This level of personalization is seen as key to promoting preventative care and potentially reducing long-term healthcare costs. For consumer-facing apps, data privacy is governed by a complex web of regulations beyond HIPAA. While HIPAA typically does not cover data collected directly from consumers, the FTC's Health Breach Notification Rule requires apps to disclose unauthorized data sharing. A growing number of states are also implementing their own laws; Washington's "My Health My Data Act," for example, mandates explicit opt-in consent before collecting or sharing consumer health data. User acquisition in the crowded health app space relies heavily on building trust before monetization. Successful strategies often involve providing free, expert-driven content and demonstrating value upfront. For communities managing chronic conditions, transparency is crucial, and founders find traction by engaging directly with patient advocacy groups and online forums to understand frustrations with existing tools and build solutions that address specific, unmet needs. Founders in the longevity and "biohacking" space are attracting venture capital by focusing on the extension of "healthspan." Startups like NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised $130 million for epigenetic reprogramming, while Retro Biosciences secured $180 million from OpenAI's Sam Altman to extend healthy lifespans. These companies leverage AI for drug discovery and aim to translate complex biological research into tangible consumer applications.